Clinical neurology and neurosurgery · 2025
Quality of sleep in chronic migraine patients treated with fremanezumab - 6 months follow-up.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stojanov Aleksandar, Stojanov Jelena, Djordjevic Gordana
Аннотация
UNLABELLED: ОBJECTIVE: Sleep disturbances are frequent in patients with chronic migraine (CM). Monoclonal antibodies, such as fremanezumab, may offer better-tolerated and efficacious alternatives to traditional migraine pharmacological preventive therapies. The aim was to assess the quality of sleep (QoS) in patients with CM, during the follow-up period of 6 months, during which they were treated with fremanezumab once per month.
METHODS: The study included 82 patients with CM and 80 healthy control subjects. The study included the application of the Pittsburgh Sleep Quality Index (PSQI), Hamilton scales for the assessment of anxiety (HAM-A) and depression (HAM-D), and the 6-item Headache Impact Test (HIT-6).
RESULTS: The PSQI global score and all subscores in patients with CM were significantly higher than in the control group (p < 0.01). We noticed a statistically significant difference between the results in the PSQI global score between the first and third testing points (p < 0.01). Also, some subscores were statistically significantly better during the follow-up period. Patients with higher scores on HIT-6, HAM-A, and HAM-D had higher scores on PSQI. Higher scores on PSQI were also noticed in female patients, the elderly, and patients with higher body mass index (BMI) levels.
CONCLUSION: The prevalence of sleep disturbance in CM patients is relatively high before starting the effective prophylactic treatment. Fremanezumab therapy had a significant beneficial influence on the QoS of CM patients. High levels of sleep disturbance correlate with higher disease-related disability, anxiety, depression, and some characteristics of the disease.
METHODS: The study included 82 patients with CM and 80 healthy control subjects. The study included the application of the Pittsburgh Sleep Quality Index (PSQI), Hamilton scales for the assessment of anxiety (HAM-A) and depression (HAM-D), and the 6-item Headache Impact Test (HIT-6).
RESULTS: The PSQI global score and all subscores in patients with CM were significantly higher than in the control group (p < 0.01). We noticed a statistically significant difference between the results in the PSQI global score between the first and third testing points (p < 0.01). Also, some subscores were statistically significantly better during the follow-up period. Patients with higher scores on HIT-6, HAM-A, and HAM-D had higher scores on PSQI. Higher scores on PSQI were also noticed in female patients, the elderly, and patients with higher body mass index (BMI) levels.
CONCLUSION: The prevalence of sleep disturbance in CM patients is relatively high before starting the effective prophylactic treatment. Fremanezumab therapy had a significant beneficial influence on the QoS of CM patients. High levels of sleep disturbance correlate with higher disease-related disability, anxiety, depression, and some characteristics of the disease.